FYERS
Indoco Remedies213.43
+0.00 (-0.84%)

Indoco Remedies Share Price

213.43+0.00 (-0.84%)
-21.23% past 1 Year

Corporate filings & documents

Announcements

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ms. Aditi M Panandikar & Ms. Madhura Suresh Kare
16 hours ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aditi M Panandikar & Others
1 day ago
Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-09-2026
6 days ago
Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-09-2026
6 days ago
Newspaper publication of Unaudited Standalone and Consolidated Financial Results for the quarter & half year ended 30-09-2026
1 week ago
Newspaper publication of Unaudited Standalone and Consolidated Financial Results for the quarter & half year ended 30-09-2026
1 week ago
Newspaper publication of Unaudited Standalone and Consolidated Financial Results for the quarter & half year ended 30-09-2026
1 week ago
Newspaper publication of Unaudited Standalone and Consolidated Financial Results for the quarter & half year ended 30-09-2026
1 week ago
Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Indocos Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities
1 week ago
Indocos Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities
1 week ago
Indocos Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities
1 week ago
Indocos Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities
1 week ago
Approval of the Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Approval of the Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Approval of the Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Approval of the Financial Results for the Quarter and Half Year Ended 30th September 2026
1 week ago
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 27th October 2026 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results
1 week ago
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 27th October 2026 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results
1 week ago
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 27th October 2026 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results
1 week ago
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 27th October 2026 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results
1 week ago
Pursuant to Regulation 30 of SEBI LODR this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 27th October 2026 has approved the allotment of 14 850 Equity shares of face value of Rs. 2 each to the Indoco Employees Welfate Trust as per Indoco Remedies Limited Employee Stock Option Plan 2022
1 week ago
Pursuant to Regulation 30 of SEBI LODR this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 27th October 2026 has approved the allotment of 14 850 Equity shares of face value of Rs. 2 each to the Indoco Employees Welfate Trust as per Indoco Remedies Limited Employee Stock Option Plan 2022
1 week ago
Pursuant to Regulation 30 of SEBI LODR this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 27th October 2026 has approved the allotment of 14 850 Equity shares of face value of Rs. 2 each to the Indoco Employees Welfate Trust as per Indoco Remedies Limited Employee Stock Option Plan 2022
1 week ago
Pursuant to Regulation 30 of SEBI LODR this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 27th October 2026 has approved the allotment of 14 850 Equity shares of face value of Rs. 2 each to the Indoco Employees Welfate Trust as per Indoco Remedies Limited Employee Stock Option Plan 2022
1 week ago
Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter and Half year ended 30th September 2026
2 weeks ago
Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter and Half year ended 30th September 2026
2 weeks ago
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 inter alia to consider and approve A meeting of the Board of Directors of the Company is scheduled to be held on Tuesday 27th October 2026 inter alia to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September 2026.
3 weeks ago
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 inter alia to consider and approve A meeting of the Board of Directors of the Company is scheduled to be held on Tuesday 27th October 2026 inter alia to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September 2026.
3 weeks ago
Attached the certificate issued by MUFG Intime India Private Ltd Registrar and Transfer Agent of the Company confirming compliance under Regulation 74(5) of SEBI(D & P) Regulations 2018 for the qtr ended 30-09-2026
4 weeks ago
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (LODR) Regulations 2015 please find enclosed a copy of the letter dispatched to shareholders holding shares in physical mode in compliance with the SEBI CIRCULAR.
1 month ago
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (LODR) Regulations 2015 please find enclosed a copy of the letter dispatched to shareholders holding shares in physical mode in compliance with the SEBI CIRCULAR.
1 month ago
Pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 please note that the Company received intimation today that the Wholly Owned Subsidiary of the Company in the name and style of Warren Lifesciences Private Limited has been incorporated on 26th September 2026 under the provisions of the Companies Act 2013
1 month ago
Pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 please note that the Company received intimation today that the Wholly Owned Subsidiary of the Company in the name and style of Warren Lifesciences Private Limited has been incorporated on 26th September 2026 under the provisions of the Companies Act 2013
1 month ago
Intimation regarding Closure of Trading Window
1 month ago
Intimation regarding Closure of Trading Window
1 month ago
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015-ESG rating
1 month ago
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015-ESG rating
1 month ago
Pursuant to Regulation 30 of SEBI LODR the Committee of Executive Directors in its meeting held today i.e. 18th September 2026 has considered and approved the incorporation of the wholly owned subsidiary Warren Lifesciences Private Limited. The said company shall be incorporated in due course.
1 month ago
Pursuant to Regulation 30 of SEBI LODR the Committee of Executive Directors in its meeting held today i.e. 18th September 2026 has considered and approved the incorporation of the wholly owned subsidiary Warren Lifesciences Private Limited. The said company shall be incorporated in due course.
1 month ago
Please find enclosed herewith the details of Voting Results and Scrutinizers Report for the 79th AGM of the Company held on 17th September 2026
1 month ago
Please find enclosed herewith the details of Voting Results and Scrutinizers Report for the 79th AGM of the Company held on 17th September 2026
1 month ago
We are submitting herewith the details regarding the Proceedings of the 79th AGM of the Company held on Thursday 17th September 2026 at 10.30 am through video conferencing(VC)/other audio video means (OAVM)
1 month ago
We are submitting herewith the details regarding the Proceedings of the 79th AGM of the Company held on Thursday 17th September 2026 at 10.30 am through video conferencing(VC)/other audio video means (OAVM)
1 month ago
UK MHRA inspection at Companys manufacturing facility at Plant I (solid oral dosage form) located at Goa.
1 month ago
UK MHRA inspection at Companys manufacturing facility at Plant I (solid oral dosage form) located at Goa.
1 month ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aditi M Panandikar & Others
1 month ago

Annual reports

FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

Oct 2026
ConcallPresentation
Jul 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Nov 2025
ConcallPresentation
Jul 2025
ConcallPresentation
May 2025
ConcallPresentation
Jan 2025
ConcallPresentation
Oct 2024
ConcallPresentation
Jul 2024
ConcallPresentation
May 2024
ConcallPresentation
Jan 2024
ConcallPresentation
Oct 2023
ConcallPresentation
Jul 2023
ConcallPresentation
May 2023
ConcallPresentation
Jan 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation

Indoco Remedies Ltd Share Price Today

The Indoco Remedies Ltd share price today is ₹250.9. During the trading session, the Indoco Remedies Ltd share price opened at ₹256 and recorded an intraday high of ₹257.7 and a low of ₹245.3. Last closing price was ₹261.67. Over the past 52 weeks, the Indoco Remedies Ltd share price has ranged between ₹162.19 and ₹317.35. The current Indoco Remedies Ltd stock price reflects real-time market activity based on executed trades on the exchange.